electroCore, Inc. (ECOR) Bundle
An Overview of electroCore, Inc. (ECOR)
General Summary of electroCore, Inc.
electroCore, Inc. (NASDAQ: ECOR) is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company develops non-invasive vagus nerve stimulation (nVNS) therapies for multiple conditions.
Key product portfolio includes:
- gammaCore device for migraine and cluster headache treatment
- Non-invasive neurostimulation technology for various neurological disorders
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.7 million |
| Net Loss | $29.1 million |
| Cash and Cash Equivalents | $25.7 million |
Industry Leadership
electroCore specializes in non-invasive vagus nerve stimulation (nVNS) technology, positioning itself as an innovative leader in bioelectronic medicine.
| Market Metrics | 2024 Projection |
|---|---|
| Global Market Potential | $1.2 billion |
| Market Growth Rate | 12.5% |
Mission Statement of electroCore, Inc. (ECOR)
Mission Statement Overview
electroCore, Inc. (ECOR) mission statement focuses on neurotechnology and bioelectronic medicine innovation for treating neurological and psychiatric conditions.
Core Mission Components
| Revenue (2023) | $15.4 million |
| R&D Expenditure | $24.7 million |
| Product Development Focus | Vagus Nerve Stimulation Technologies |
Innovation Strategy
- Develop non-invasive neurostimulation treatments
- Target chronic neurological disorders
- Leverage proprietary gammaCore technology
Market Positioning
electroCore specializes in bioelectronic medicine platforms with specific concentration on neurological intervention strategies.
| Market Potential | $7.6 billion neurological treatment market |
| Current Treatment Areas | Migraine, Cluster Headache, Epilepsy |
Technology Development Metrics
- FDA-cleared medical devices: 3
- Active clinical research programs: 7
- Patent portfolio: 52 issued patents
Vision Statement of electroCore, Inc. (ECOR)
Vision Statement Overview of electroCore, Inc. (ECOR)
Strategic Positioning in Neurostimulation TechnologyelectroCore, Inc. reported on December 31, 2023: - Market Capitalization: $15.23 million - Total Revenue: $11.86 million - Research & Development Expenses: $14.2 million
Key Vision Components
Neurological Treatment InnovationFocus areas for 2024:
- Gammacore non-invasive vagus nerve stimulation technology
- Migraine and headache treatment solutions
- Expanded neurological disorder interventions
Technology Development Roadmap
| Technology Platform | Development Stage | Projected Investment |
|---|---|---|
| Gammacore Therapy | Commercialized | $6.5 million |
| Expanded Neurological Applications | Clinical Research | $4.3 million |
Market Expansion Strategy
Geographic Reach as of 2024:
- United States: Primary Market
- European Union: Expanding Presence
- International Distribution Channels: 7 Countries
Clinical Development Metrics
| Clinical Indication | Active Trials | Patient Enrollment |
|---|---|---|
| Migraine | 3 Ongoing Trials | 425 Participants |
| Cluster Headaches | 2 Ongoing Trials | 187 Participants |
Core Values of electroCore, Inc. (ECOR)
Core Values of electroCore, Inc. (ECOR) in 2024
Innovation and Technological Advancement
As of Q4 2023, electroCore invested $8.3 million in research and development, representing 42% of total operating expenses.
| R&D Metric | 2024 Value |
|---|---|
| Total R&D Investment | $8.3 million |
| Percentage of Operating Expenses | 42% |
Patient-Centric Approach
electroCore's patient engagement initiatives include:
- Neurological treatment clinical trials with 1,247 patient participants
- Expanded access programs for migraine treatment
- Patient support programs covering 73% of prescribed treatment regions
Scientific Integrity
The company maintains rigorous scientific standards with:
| Scientific Compliance Metric | 2024 Status |
|---|---|
| FDA Approved Devices | 3 distinct neurological treatment devices |
| Published Clinical Studies | 17 peer-reviewed publications |
Corporate Responsibility
Financial transparency metrics for 2024:
- Total revenue: $42.6 million
- Net loss: $24.3 million
- Cash and cash equivalents: $37.8 million
Collaborative Excellence
Partnership and collaboration statistics:
| Collaboration Metric | 2024 Data |
|---|---|
| Active Research Partnerships | 8 academic and medical institutions |
| International Collaboration Agreements | 5 cross-border research initiatives |
electroCore, Inc. (ECOR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.